Gastric Cancer Pipeline Landscape Review, H1 2020 -

DUBLIN--()--The "Gastric Cancer - Pipeline Review, H1 2020" drug pipelines has been added to's offering.

This Pharmaceutical and Healthcare pipeline guide provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 16, 113, 169, 1, 15, 148, 27 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 9, 1, 8 and 4 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • 3SBio Inc
  • AbbVie Inc
  • AbClon Inc
  • AbGenomics International Inc
  • Abion Inc
  • ABL Bio Inc
  • Abpro Corp
  • Acepodia Biotech Inc
  • Acrotech Biopharma LLC
  • AD Pharmaceuticals Co Ltd
  • Adaptimmune Therapeutics Plc
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Affimed GmbH
  • AffyImmune Therapeutics Inc
  • AIMM Therapeutics BV
  • Akeso Biopharma Inc
  • Alkermes Plc
  • Alligator Bioscience AB
  • Alphamab Oncology
  • Alteogen Inc
  • Ambrx Inc
  • amcure GmbH
  • Amgen Inc
  • Andes Biotechnologies
  • Anew Oncology Inc
  • Antapodia Therapeutics Inc
  • Antikor Biopharma Ltd
  • Apollomics Inc
  • Apotex Inc
  • Arbele Ltd
  • Argonaut Therapeutics Ltd
  • Arromax Pharmatech Co Ltd
  • Asana BioSciences LLC
  • Ascelia Pharma AB
  • Ascenta Therapeutics Inc
  • AskAt Inc
  • Aslan Pharmaceuticals Ltd
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Aurigene Discovery Technologies Ltd
  • Aurora BioPharma Inc
  • Basilea Pharmaceutica Ltd
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Beijing BGI-GBI Biotech Co Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Beijing Mabworks Biotech Co Ltd
  • and many, many more!

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900